Introduction {#sec1}
============

Cancer prevalence increases rapidly and becomes a major threat to human health in today's world. As we all know, genes are inextricably linked to the development of cancer. In many cancer studies, such as gastric cancer \[[@B1]\], colorectal cancer, breast cancer \[[@B2]\], cervical cancer \[[@B3]\], Toll-like receptor (TLR)-2 (*TLR2*) has been determined as a pathogenic factor involved in tumorigenesis. The *TLR2* gene located on human chromosome 4q32, includes one coding exon and two non-coding exons \[[@B4]\]. TLRs are mainly expressed in immune-related cells and immune-related epithelial cells, their role in tissue resistance to microbes is achieved by identifying conserved bacterial molecules \[[@B5]\]. Therefore some researchers believe that *TLR2* play a significant role in the innate immune response through releasing pro-inflammatory cytokines \[[@B6]\].

-196 to -174del is a 22-bp deletion in *TLR2* gene, which has been shown to cause a decrease in the transcriptional activity of the *TLR2* gene \[[@B7]\]. However, in the past few years, there are inconsistent conclusions about the relationship between -196 to -174del and cancer risk. One paper noted that -196 to -174del in association with *Helicobacter pylori* significantly increased the risk of gastric cancer in patients \[[@B1]\]. But Hishida et al. \[[@B8]\] suggested that -196 to -174del had no relationship with gastric cancer. About reproductive tumors, some literatures suggested that -196 to -174del is not associated with breast cancer \[[@B9]\] and cervical cancer \[[@B3]\], but on the contrary, Theodoropoulos et al. \[[@B10]\] think that -196 to -174del may produce a significant increase in the risk of breast cancer. Mandal et al. \[[@B11]\] revealed that -196 to -174del polymorphism in *TLR2* gene seems to be associated with the upgraded prostate cancer risk, while Singh et al. \[[@B12]\] drew out that -196 to -174del showed a three- to five-folds risk of bladder cancer comparison with people without this mutation.

For rs3804099 (c.597T\>C) and rs3804100 (c.1350T\>C), Etokebe et al. \[[@B13]\] and Semlali et al. \[[@B14]\] found no association between these two SNPs and breast cancer; Tongtawee et al. \[[@B15]\] demonstrated that rs3804099 and rs3804100 had no relationship with gastric cancer. However, the study of Xie et al. \[[@B16]\] found that the risk of hepatocellular carcinoma in *TLR2* rs3804099 and rs3804100 carriers was reduced. For rs4696480 (g.6686T\>A), de Barros Gallo et al. \[[@B17]\] thought that rs4696480 was associated with oral cancer in Caucasians, but Semlali et al. \[[@B18]\] found no difference in rs4696480 expression between the breast cancer patients and the controls in Asians.

Therefore, considering the limitations of individual study sample sizes and the contradictions of their conclusions, we designed this meta-analysis to study the relationship between *TLR2* polymorphisms. (rs3804099, rs3804100, rs4696480, rs5743708 (c.2258G\> A), rs1898830 (g.8013A\> G) and -196 to -174del) and cancer risk.

Materials and methods {#sec2}
=====================

Database searching {#sec2-1}
------------------

Up to October 2019, PubMed, Embase, Google Scholar, Web of Science, Wanfang database and CNKI database were used by two investigators for article identification. We used the following strategy for the searching of relevant citations: (TLR2 OR (Toll-like receptors-2) OR CD282) AND (cancer OR tumor OR carcinoma OR neoplasms OR malignancy) AND (polymorphism OR mutation OR variant OR SNP OR genotype). Since the present study is a meta-analysis, no institutional review board approval and patient consent were required.

Inclusion and exclusion criteria {#sec2-2}
--------------------------------

Articles included in our research must meet the following conditions: (1) study the relationship between cancer risk and *TLR2* polymorphism; (2) provide sufficient data for extraction and calculation; (3) subjects are human patients; (4) the case--control study included control group and cancer patients case group. When duplicate data appeared in different publications, only the latest publication data were used. If the study did not meet the above criteria, it was excluded.

Data extraction and quality assessment {#sec2-3}
--------------------------------------

We extracted data from these articles, such as cancer type, first author, ethnicity, source of control, publication year, number of cases and controls, etc. Any differences were resolved through group discussions until all consensus was reached. We used Newcastle--Ottawa Scale (NOS) to evaluate the quality of the article (<http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp>). We carefully recorded seven aspects including 'adequacy of case definition', 'representativeness of the cases', 'selection of controls', 'definition of controls', 'comparability cases/controls', 'ascertainment of exposure' and 'ascertainment of exposure' to evaluate.

Statistical analysis {#sec2-4}
--------------------

The STATA software was used for meta-statistical analysis. The relationship between the *TLR2* rs3804099, rs3804100, rs4696480, rs5743708, rs1898830, -196 to -174del and cancer risk was assessed using pooled odds ratios (ORs) with 95% confidence intervals (95% CIs) under dominant, recessive, homozygous codominance, heterozygous codominance, and allelic control genetic models. Heterogeneity was estimated using Q test and *I^2^* statistics \[[@B19]\]. When heterogeneity existed (*P*\<0.1), random-effects model was applied, otherwise, fixed-effect model was used \[[@B20]\]. The Hardy--Weinberg equilibrium (HWE) of the control group was calculated using the chi-square test. In addition, we performed a stratified analysis based on cancer type, race, source of control and quality score. The sensitivity analysis was used to evaluate the stability of the overall analysis and the publication bias was evaluated by Egger's test and Begg's funnel plot \[[@B21]\].

False-positive report probability analysis and trial sequential analysis {#sec2-5}
------------------------------------------------------------------------

We also used the false-positive report probability (FPRP) to evaluate the results; 0.2 was set as thePRP threshold and assigned a prior probability of 0.25 to detect the OR of 0.67/1.50 (protective/risk effects). The significant result with the FPRP values less than 0.2 were considered a worthy finding \[[@B22],[@B23]\]. Trial sequential analysis (TSA) was conducted with the guideline of a former publication \[[@B24],[@B25]\]. We set a significance of 5% for type I error, as well as a 30% significance of type II error, to calculate the required sample size, and built the TSA monitoring boundaries.

*In silico* analysis {#sec2-6}
--------------------

For evaluating the linkage disequilibrium (LD) between different polymorphisms, we downloaded the dataset including the polymorphisms information of *TLR2* gene from the 1000 Genomes Project, which contained the distribution of gene polymorphisms among CHB (Han Chinese in Beijing, China), CHS (southern Han Chinese, China), CEU (Utah residents with Northern and Western European ancestry from the CEPH collection), JPT (Japanese in Tokyo, Japan) and YRI (Yoruba in Ibadan, Nigeria), ESN (Esan in Nigeria) patients, and we used Haplpoview software to visualize the association between different polymorphisms, the relationship between them were assessed by r^2^ statistics. We also performed the expression quantitative trait loci (eQTL) analysis using GTEx portal website (<http://www.gtexportal.org/home/>) to predict potential associations between the SNPs and gene expression levels \[[@B26],[@B27]\].

Results {#sec3}
=======

Search results {#sec3-1}
--------------

We used online databases to find 242 articles, and found another 36 articles by reviewing the references. After removing the duplicates, we found a total of 268 records in the database. We first screened the duplicate articles and then screened 43 of the high-quality articles on the NOS (Supplementary Table S1). Of the 43 articles selected, 13 were rejected for insufficient data. At last, 30 articles met the criteria, including 47 case--control studies. The flowchart of our study selection is shown in [Figure 1](#F1){ref-type="fig"}. This meta-analysis collected individuals with different genetic backgrounds (e.g. Asians, Africans and Caucasians). The detailed characteristics of these publications are provided in [Table 1](#T1){ref-type="table"}.

![Flowchart of enrolled studies selection procedure](bsr-39-bsr20191698-g1){#F1}

###### Characteristics of the enrolled studies on *TLR2* polymorphism and cancer

  First author               Year    Ethnicity   Genotyping method   Source of control   Cancer type                Cases   Control                                                                            
  -------------------------- ------- ----------- ------------------- ------------------- -------------------------- ------- --------- ------ ------ ------- ------- ------ ------ ----- ------ ------- ------- ---
  **(-196 to -174del)**                                                                                                                                                                                        
  Tahara et al.              2007    Asian       AS-PCR              PB                  Gastric cancer             126     112       51     289    63.0%   37.0%   73     65     8     146    72.3%   27.7%   Y
  Pandey et al.              2009    Asian       PCR                 PB                  Cervical cancer            102     43        5      150    82.3%   17.7%   114    35     1     150    87.7%   12.3%   Y
  Hishida et al.             2010    Asian       PCR                 HB                  Gastric cancer             243     267       73     583    64.6%   35.4%   722    730    184   1636   66.4%   33.6%   Y
  Srivastava et al.          2010    Asian       PCR-RFLP            PB                  Gallbladder cancer         132     94        6      232    77.2%   22.8%   163    87     4     254    81.3%   18.7%   N
  Zeng et al.                2011a   Asian       DHPLC               HB                  Gastric cancer             119     110       19     248    70.2%   29.8%   187    246    63    496    62.5%   37.5%   Y
  Nischalk et al.            2011    Caucasian   PCR                 PB                  Hepatocellular carcinoma   115     63        11     189    77.5%   22.5%   248    92     7     347    84.7%   15.3%   Y
  Oliveira et al.            2012    Caucasian   PCR-RFLP            PB                  Gastric cancer             116     50        8      174    81.0%   19.0%   189    34     2     225    91.6%   8.4%    Y
  Mandal et al.              2012    Asian       PCR                 PB                  Prostate cancer            135     54        6      195    83.1%   16.9%   193    52     5     250    87.6%   12.4%   Y
  Theodoropoulos et al.      2012    Caucasian   PCR                 PB                  Breast cancer              120     113       28     261    67.6%   32.4%   432    46     2     480    94.8%   5.2%    Y
  Singh et al.               2013    Asian       PCR                 PB                  Bladder cancer             110     79        11     200    74.8%   25.3%   119    73     8     200    77.8%   22.3%   Y
  Bi et al.                  2014    Asian       PCR                 PB                  Cervical cancer            40      47        15     102    62.3%   37.7%   36     50     14    100    61.0%   39.0%   Y
  Castano-Rodriguez et al.   2014    Asian       MassARRAY           HB                  Gastric cancer             7       44        35     86     33.7%   66.3%   19     95     106   220    30.2%   69.8%   Y
  Zidi et al.                2014    African     PCR                 HB                  Cervical cancer            89      20        13     122    81.1%   18.9%   196    37     27    260    82.5%   17.5%   N
  Devi et al.                2015    Asian       PCR                 PB                  Breast cancer              251     191       20     462    75.0%   25.0%   491    246    33    770    79.7%   20.3%   Y
  Proenca et al.             2015    African     PCR                 PB                  Colorectal cancer          144     39        5      188    87.0%   13.0%   200    36     4     240    90.8%   9.2%    Y
  Zidi et al.                2015    African     PCR                 PB                  Cervical cancer            93      26        11     130    81.5%   18.5%   196    37     27    260    82.5%   17.5%   N
  AL-Harras et al.           2016    African     PCR-RFLP            PB                  Breast cancer              44      22        6      72     76.4%   23.6%   61     33     6     100    77.5%   22.5%   Y
  Huang et al.               2018    Asian       PCR                 PB                  Gastric cancer             105     124       31     260    64.2%   35.8%   132    113    15    260    72.5%   27.5%   Y
  **rs3804099**                                                                                                                                                                                                
  Etokebe et al.             2009    Caucasian   TaqMan              PB                  Breast cancer              29      44        16     89     57.3%   42.7%   26     48     15    89     56.2%   43.8%   Y
  Slattery et al.            2012    Caucasian   GoldenGate          PB                  Colon cancer               1255    300       1555   \-     \-      1531    425    1956   \-    \-     \-              
  Xie et al.                 2012    Asian       SNaPshot            HB                  Hepatocellular carcinoma   19      71        121    211    25.8%   74.2%   15     117    100   232    31.7%   68.3%   N
  Miedema et al.             2012    Caucasian   AS-PCR              HB                  Lymphoblastic leukemia     51      94        37     182    53.8%   46.2%   48     102    28    178    55.6%   44.4%   N
  Slattery et al.            2012    Caucasian   GoldenGate          PB                  Rectal cancer              238     372       144    754    56.2%   43.8%   299    477    183   959    56.0%   44.0%   Y
  Zeljic et al.              2013    Caucasian   TaqMan              PB                  Oral cancer                29      39        25     93     52.2%   47.8%   37     67     0     104    67.8%   32.2%   N
  Semlali et al.             2017    Asian       TaqMan              PB                  Breast cancer              35      58        32     125    51.2%   48.8%   33     71     42    146    46.9%   53.1%   Y
  Semlali et al.             2018    Asian       TaqMan              PB                  Colon cancer               42      50        19     111    60.4%   39.6%   28     47     27    102    50.5%   49.5%   Y
  Tongtawee et al.           2018    Asian       TaqMan              HB                  Gastric cancer             62      13        13     88     77.8%   22.2%   194    56     62    312    71.2%   28.8%   N
  Zeng et al.                2011b   Asian       PCR-RFLP            HB                  Gastric cancer             132     99        17     248    73.2%   26.8%   216    231    49    496    66.8%   33.2%   Y
  **rs3804100**                                                                                                                                                                                                
  Purdu et al.               2008    Caucasian   TaqMan              PB                  Non-Hodgkin lymphoma       1658    272       12     1942   92.4%   7.6%    1556   233    9     1798   93.0%   7.0%    Y
  Etokebe et al.             2009    Caucasian   TaqMan              PB                  Breast cancer              76      13        0      89     92.7%   7.3%    84     11     0     95     94.2%   5.8%    Y
  Xie et al.                 2012    Asian       SNaPshot            HB                  Hepatocellular carcinoma   14      67        130    211    22.5%   77.5%   11     110    111   232    28.4%   71.6%   N
  Miedema et al.             2012    Caucasian   AS-PCR              HB                  Lymphoblastic leukemia     170     18        1      189    94.7%   5.3%    165    18     0     183    95.1%   4.9%    Y
  Castano-Rodriguez et al.   2014    Asian       MassARRAY           HB                  Gastric cancer             47      34        4      85     75.3%   24.7%   122    76     14    212    75.5%   24.5%   Y
  Semlali et al.             2017    Asian       TaqMan              PB                  Breast cancer              99      24        1      124    89.5%   10.5%   115    27     4     146    88.0%   12.0%   Y
  Semlali et al.             2018    Asian       TaqMan              PB                  Colon cancer               99      13        2      114    92.5%   7.5%    82     19     2     103    88.8%   11.2%   Y
  Tongtawee et al.           2018    Asian       TaqMan              HB                  Gastric cancer             66      22        0      88     87.5%   12.5%   230    70     12    312    84.9%   15.1%   N
  **rs4696480**                                                                                                                                                                                                
  Miedema et al.             2012    Caucasian   AS-PCR              HB                  Hepatocellular carcinoma   42      99        44     185    49.5%   50.5%   60     83     38    181    56.1%   43.9%   Y
  Gallo et al.               2017    Caucasian   TaqMan              PB                  Oral cancer                12      39        24     75     42.0%   58.0%   31     34     24    89     53.9%   46.1%   N
  Semlali et al.             2017    Asian       TaqMan              PB                  Breast cancer              46      51        29     126    56.7%   43.3%   50     63     25    138    59.1%   40.9%   Y
  Semlali et al.             2018    Asian       TaqMan              PB                  Colon cancer               30      49        27     106    51.4%   48.6%   26     41     25    92     50.5%   49.5%   Y
  **rs5743708**                                                                                                                                                                                                
  Nischalk et al.            2011    Caucasian   PCR                 PB                  Hepatocellular carcinoma   174     15        0      189    96.0%   4.0%    319    28     0     347    96.0%   4.0%    Y
  Slattery et al.            2012    Caucasian   GoldenGate          PB                  Rectal cancer              727     27        754    \-     \-      913     46     959    \-    \-                     
  Slattery et al.            2012    Caucasian   GoldenGate          PB                  Colon cancer               1467    88        1555   \-     \-      1864    92     1956   \-    \-                     
  Kina et al.                2018    Caucasian   PCR                 PB                  Glioma                     32      18        70     120    34.2%   65.8%   184    35     6     225    89.6%   10.4%   N
  **rs1898830**                                                                                                                                                                                                
  Xie et al.                 2012    Asian       SNPshot             HB                  Hepatocellular carcinoma   47      92        72     211    44.1%   55.9%   34     118    80    232    40.1%   59.9%   Y
  Slattery et al.            2012    Caucasian   GoldenGate          PB                  Rectal cancer              305     363       86     754    64.5%   35.5%   410    437    111   958    65.6%   34.4%   Y
  Slattery et al.            2012    Caucasian   GoldenGate          PB                  Colon cancer               705     674       176    1555   67.0%   33.0%   896    833    227   1956   67.1%   32.9%   Y

Abbreviations: H-B, hospital based; P-B, population based. *P*\>0.05 means conformed to HWE.

Meta-analysis results {#sec3-2}
---------------------

The results of pooled analysis for *TLR2* polymorphism and cancer susceptibility are provided in [Table 2](#T2){ref-type="table"}. For -196 to -174del, we collected 18 articles containing 3943 cases and 4574 controls \[[@B1],[@B6],[@B8],[@B28]\]. In the overall analysis, -196 to -174del significantly increased the risk of cancer \[B vs. A (OR = 1.468, 95% Cl = 1.129--1.91, *P*=0.005); BB vs. AA (OR = 1.716, 95% Cl = 1.178--2.5, *P*=0.005); BA vs. AA (OR = 1.408, 95% Cl = 1.092--1.816, *P*=0.008); BB+BA vs. AA (OR = 1.449, 95% Cl = 1.107--1.897, *P*=0.007); BB vs. BA+AA (OR = 1.517, 95% Cl = 1.092--2.107, *P*=0.013)\] ([Figure 2](#F2){ref-type="fig"}). Among the subgroup of Caucasians, -196 to -174del produces a significant increase in the risk of cancer, too \[B vs. A (OR = 3.291, 95% Cl = 1.139--9.51, *P*=0.028); BB vs. AA (OR = 9.878, 95% Cl = 1.83--53.322, *P*=0.008); BA vs. AA (OR = 3.156, 95% Cl = 1.034--9.634, *P*=0.044); BB+BA vs. AA (OR = 3.555, 95% Cl = 1.098--11.51, *P*=0.034); BB vs. BA+AA (OR = 7.294, 95% Cl = 1.752-30.369, *P*=0.006)\]. During the subgroup analysis of HB, -196 to -174del was found to be associated with cancer \[B vs. A (OR = 1.576, 95% Cl = 1.193--2.08, *P*\<0.001); BB vs. AA (OR = 2.274, 95% Cl = 1.43--3.616, *P*\<0.001); BA vs. AA (OR = 1.543, 95% Cl = 1.143--2.081, *P*\<0.001); BB+BA vs. AA (OR = 1.624, 95% Cl = 1.186--2.223, *P*\<0.001); BB vs. BA+AA (OR = 2.011, 95% Cl = 1.317--3.07, *P*=0.001)\]. In addition, in the subgroup analysis of Asians, the models of BB+BA vs. AA (OR = 1.203, 95% Cl = 1.015--1.427, *P*=0.033) and B vs. A (OR = 1.169, 95% Cl = 1.005--1.361, *P*=0.043) suggested that -196 to -174del increased the risk of cancer. Meanwhile, when -196 to -174del conformed to HWE in the control group, analysis of all models showed that the deletion of these 22 genes increased the risk of cancer (Supplementary Table S2). By the way, the BA vs. AA model in the N subgroup suggested that -196 to-174del was related to the cancer risk (OR = 1.335, 95% Cl = 1.015--1.757, *P*=0.039).

![Meta-analysis of the association between *TLR2* -196 to -174 del polymorphism and cancer risk](bsr-39-bsr20191698-g2){#F2}

###### Results of pooled analysis for *TLR2* polymorphism and cancer susceptibility

  Comparison          Subgroup          *n*   Cases   Controls   *P*~H~    *P*~Z~    HR (95% CI)
  ------------------- ----------------- ----- ------- ---------- --------- --------- -----------------------
  (-196 to -174del)                                                                  
  B vs. A             Overall           18    3943    6394       \<0.001   0.005\*   1.468 (1.129--1.91)
  BB vs. AA           Overall           18    3943    6394       \<0.001   0.005\*   1.716 (1.178--2.5)
  BA vs. AA           Overall           18    3943    6394       \<0.001   0.008\*   1.408 (1.092--1.816)
  BB+BA vs. AA        Overall           18    3943    6394       \<0.001   0.007\*   1.449 (1.107--1.897)
  BB vs. BA+ AA       Overall           18    3943    6394       \<0.001   0.013\*   1.517 (1.092--2.107)
  B vs. A             Asian             11    2807    4482       \<0.001   0.043\*   1.169 (1.005--1.361)
  BB vs. AA           Asian             11    2807    4482       0.003     0.098     1.373 (0.943--2)
  BA vs. AA           Asian             11    2807    4482       0.039     0.054     1.168 (0.997--1.367)
  BB+BA vs. AA        Asian             11    2807    4482       0.008     0.033\*   1.203 (1.015--1.427)
  BB vs. BA+ AA       Asian             11    2807    4482       0.005     0.177     1.256 (0.902--1.748)
  B vs. A             Caucasian         3     624     1052       \<0.001   0.028\*   3.291 (1.139--9.51)
  BB vs. AA           Caucasian         3     624     1052       0.007     0.008\*   9.878 (1.83--53.322)
  BA vs. AA           Caucasian         3     624     1052       \<0.001   0.044\*   3.156 (1.034--9.634)
  BB+BA vs. AA        Caucasian         3     624     1052       \<0.001   0.034\*   3.555 (1.098--11.51)
  BB vs. BA+ AA       Caucasian         3     624     1052       0.029     0.006\*   7.294 (1.752--30.369)
  B vs. A             African           4     512     860        0.653     0.159     1.163 (0.943--1.436)
  BB vs. AA           African           4     512     860        0.796     0.746     1.076 (0.693--1.67)
  BA vs. AA           African           4     512     860        0.652     0.075     1.296 (0.974--1.724)
  BB+BA vs. AA        African           4     512     860        0.72      0.106     1.232 (0.956--1.586)
  BB vs. BA+AA        African           4     512     860        0.755     0.897     1.029 (0.666--1.59)
  B vs. A             PB                14    2904    3782       \<0.001   0.001\*   1.576 (1.193--2.08)
  BB vs. AA           PB                14    2904    3782       \<0.001   0.001\*   2.274 (1.43--3.616)
  BA vs. AA           PB                14    2904    3782       \<0.001   0.005\*   1.543 (1.143--2.081)
  BB+BA vs. AA        PB                14    2904    3782       \<0.001   0.002\*   1.624 (1.186--2.223)
  BB vs. BA+AA        PB                14    2904    3782       0.001     0.001\*   2.011 (1.317--3.07)
  B vs. A             HB                4     1039    2612       0.016     0.502     0.92 (0.721--1.173)
  BB vs. AA           HB                4     1039    2612       0.048     0.552     0.866 (0.54--1.39)
  BA vs. AA           HB                4     1039    2612       0.122     0.841     0.984 (0.837--1.156)
  BB+BA vs. AA        HB                4     1039    2612       0.038     0.716     0.942 (0.684--1.298)
  BB vs. BA+AA        HB                4     1039    2612       0.121     0.43      0.917 (0.739--1.138)
  B vs. A             Gastric cancer    6     1640    2983       \<0.001   0.194     1.22 (0.904--1.647)
  BB vs. AA           Gastric cancer    6     1640    2983       \<0.001   0.176     1.565 (0.818--2.995)
  BA vs. AA           Gastric cancer    6     1640    2983       0.002     0.309     1.171 (0.864--1.586)
  BB+BA vs. AA        Gastric cancer    6     1640    2983       \<0.001   0.216     1.246 (0.879--1.764)
  BB vs. BA+AA        Gastric cancer    6     1640    2983       \<0.001   0.223     1.401 (0.814--2.411)
  B vs. A             Breast cancer     3     795     1350       \<0.001   0.212     2.31 (0.621--8.593)
  BB vs. AA           Breast cancer     3     795     1350       \<0.001   0.2       4.049 (0.478--34.306)
  BA vs. AA           Breast cancer     3     795     1350       \<0.001   0.197     2.347 (0.642--8.58)
  BB+BA vs. AA        Breast cancer     3     795     1350       \<0.001   0.2       2.52 (0.613--10.36)
  BB vs. BA+AA        Breast cancer     3     795     1350       \<0.001   0.233     3.176 (0.476--21.196)
  B vs. A             Cervical cancer   4     504     770        0.474     0.269     1.121 (0.916--1.372)
  BB vs. AA           Cervical cancer   4     504     770        0.453     0.782     1.061 (0.696--1.618)
  BA vs. AA           Cervical cancer   4     504     770        0.554     0.177     1.215 (0.916--1.613)
  BB+BA vs. AA        Cervical cancer   4     504     770        0.586     0.207     1.177 (0.914--1.515)
  BB vs. BA+AA        Cervical cancer   4     504     770        0.456     0.848     1.041 (0.692--1.566)
  B vs. A             Y                 15    3459    5620       \<0.001   0.008\*   1.447 (1.103--1.897)
  BB vs. AA           Y                 15    3459    5620       \<0.001   0.004\*   1.915 (1.227--2.991)
  BA vs. AA           Y                 15    3459    5620       \<0.001   0.02\*    1.422 (1.057--1.915)
  BB+BA vs. AA        Y                 15    3459    5620       \<0.001   0.013\*   1.494 (1.088--2.052)
  BB vs. BA+AA        Y                 15    3459    5620       \<0.001   0.009\*   1.673 (1.137--2.461)
  B vs. A             N                 3     484     774        0.709     0.14      1.168 (0.951--1.434)
  BB vs. AA           N                 3     484     774        0.597     0.84      1.05 (0.655--1.681)
  BA vs. AA           N                 3     484     774        0.872     0.039\*   1.335 (1.015--1.757)
  BB+BA vs. AA        N                 3     484     774        0.839     0.07      1.258 (0.981--1.613)
  BB vs. BA+AA        N                 3     484     774        0.615     0.959     0.988 (0.62--1.575)
  rs3804099                                                                          
  B vs. A             Overall           9     1901    2618       0.001     0.723     0.967 (0.806--1.162)
  BB vs. AA           Overall           9     1901    2618       0.029     0.29      0.84 (0.609--1.16)
  BA vs. AA           Overall           9     1901    2618       0.643     0.008\*   0.827 (0.717--0.952)
  BB+BA vs. AA        Overall           9     1901    2618       0.446     0.016\*   0.85 (0.744--0.97)
  BB vs. BA+AA        Overall           10    3456    4574       0.001     0.946     0.991 (0.768--1.28)
  B vs. A             Asian             5     783     1288       0.013     0.177     0.838 (0.648--1.083)
  BB vs. AA           Asian             5     783     1288       0.721     0.005\*   0.65 (0.482--0.877)
  BA vs. AA           Asian             5     783     1288       0.892     0.001\*   0.69 (0.55--0.867)
  BB+BA vs. AA        Asian             5     783     1288       0.994     \<0.001   0.684 (0.555--0.843)
  BB vs. BA+AA        Asian             5     783     1288       0.005     0.559     0.869 (0.542--1.393)
  B vs. A             Caucasian         4     1118    1330       0.025     0.3       1.147 (0.885--1.486)
  BB vs. AA           Caucasian         4     1118    1330       0.024     0.455     1.283 (0.667--2.47)
  BA vs. AA           Caucasian         4     1118    1330       0.819     0.425     0.929 (0.774--1.114)
  BB+BA vs. AA        Caucasian         4     1118    1330       0.87      0.866     0.985 (0.829--1.171)
  BB vs. BA+AA        Caucasian         5     2673    3286       0.01      0.647     1.082 (0.771--1.518)
  B vs. A             Breast cancer     2     214     235        0.647     0.364     0.885 (0.68--1.152)
  BB vs. AA           Breast cancer     2     214     235        0.611     0.399     0.796 (0.47--1.351)
  BA vs. AA           Breast cancer     2     214     235        0.887     0.302     0.792 (0.509--1.233)
  BB+BA vs. AA        Breast cancer     2     214     235        0.765     0.276     0.793 (0.523--1.203)
  BB vs. BA+AA        Breast cancer     2     214     235        0.621     0.713     0.921 (0.592--1.432)
  B vs. A             Gastric Cancer    2     336     808        0.831     0.002\*   0.728 (0.594--0.893)
  BB vs. AA           Gastric Cancer    2     336     808        0.75      0.026\*   0.605 (0.389--0.942)
  BA vs. AA           Gastric Cancer    2     336     808        0.926     0.018\*   0.706 (0.529--0.942)
  BB+BA vs. AA        Gastric Cancer    2     336     808        0.956     0.004\*   0.681 (0.524--0.886)
  BB vs. BA+AA        Gastric Cancer    2     336     808        0.928     0.083     0.683 (0.444--1.051)
  BB vs. BA+ AA       Colon Cancer      2     1666    2058       0.243     0.034\*   0.841 (0.716--0.987)
  B vs. A             PB                5     1172    1400       0.004     0.985     0.997 (0.759--1.311)
  BB vs. AA           PB                5     1172    1400       0.01      0.762     0.912 (0.502--1.658)
  BA vs. AA           PB                5     1172    1400       0.764     0.252     0.901 (0.754--1.077)
  BB+BA vs. AA        PB                5     1172    1400       0.468     0.385     0.928 (0.785--1.098)
  BB vs. BA+AA        PB                6     2727    3356       0.021     0.549     0.915 (0.683--1.225)
  B vs. A             HB                4     729     1218       0.007     0.658     0.934 (0.691--1.263)
  BB vs. AA           HB                4     729     1218       0.29      0.155     0.794 (0.577--1.091)
  BA vs. AA           HB                4     729     1218       0.624     0.005\*   0.713 (0.564--0.902)
  BB+BA vs. AA        HB                4     729     1218       0.679     0.005\*   0.734 (0.591--0.912)
  BB vs. BA+AA        HB                4     729     1218       0.012     0.782     1.073 (0.65--1.772)
  B vs. A             Y                 5     1327    1792       0.13      0.036\*   0.895 (0.807--0.993)
  BB vs. AA           Y                 5     1327    1792       0.233     0.087     0.828 (0.668--1.028)
  BA vs. AA           Y                 5     1327    1792       0.484     0.058     0.856 (0.729--1.005)
  BB+BA vs. AA        Y                 5     1327    1792       0.258     0.028\*   0.844 (0.725--0.982)
  BB vs. BA+ AA       Y                 5     1327    1792       0.437     0.265     0.898 (0.742--1.086)
  B vs. A             N                 4     574     826        0.004     0.37      1.179 (0.823--1.688)
  BB vs. AA           N                 4     574     826        0.008     0.596     1.262 (0.534--2.98)
  BA vs. AA           N                 4     574     826        0.628     0.042\*   0.73 (0.54--0.988)
  BB+BA vs. AA        N                 4     574     826        0.469     0.315     0.87 (0.663--1.142)
  BB vs. BA+AA        N                 4     574     826        0.002     0.242     1.564 (0.739--3.308)
  rs3804100                                                                          
  B vs. A             Overall           8     2842    3081       0.422     0.254     1.076 (0.949--1.219)
  BB vs. AA           Overall           8     2842    3081       0.682     0.412     0.823 (0.516--1.311)
  BA vs. AA           Overall           8     2842    3081       0.487     0.603     1.041 (0.896--1.209)
  BB+BA vs. AA        Overall           8     2842    3081       0.758     0.641     1.035 (0.894--1.199)
  BB vs. BA+AA        Overall           8     2842    3081       0.243     0.061     1.343 (0.987--1.827)
  B vs. A             Asian             5     622     1005       0.152     0.71      1.037 (0.856--1.257)
  BB vs. AA           Asian             5     622     1005       0.66      0.153     0.655 (0.366--1.17)
  BA vs. AA           Asian             5     622     1005       0.276     0.543     0.917 (0.692--1.213)
  BB+BA vs. AA        Asian             5     622     1005       0.688     0.391     0.888 (0.677--1.165)
  BB vs. BA+AA        Asian             5     622     1005       0.105     0.079     1.346 (0.966--1.875)
  B vs. A             Caucasian         3     2220    2076       0.937     0.237     1.105 (0.937--1.304)
  BB vs. AA           Caucasian         3     2220    2076       0.618     0.494     1.337 (0.582--3.075)
  BA vs. AA           Caucasian         3     2220    2076       0.87      0.317     1.095 (0.917--1.308)
  BB+BA vs. AA        Caucasian         3     2220    2076       0.908     0.268     1.104 (0.927--1.315)
  BB vs. BA+AA        Caucasian         3     2220    2076       0.612     0.51      1.323 (0.576--3.039)
  B vs. A             PB                4     2269    2142       0.365     0.555     1.049 (0.896--1.228)
  BB vs. AA           PB                4     2269    2142       0.471     0.91      0.959 (0.465--1.977)
  BA vs. AA           PB                4     2269    2142       0.402     0.495     1.061 (0.894--1.26)
  BB+BA vs. AA        PB                4     2269    2142       0.384     0.514     1.057 (0.894--1.251)
  BB vs. BA+ AA       PB                4     2269    2142       0.479     0.911     0.96 (0.466--1.978)
  B vs. A             HB                4     573     939        0.308     0.266     1.124 (0.915--1.381)
  BB vs. AA           HB                4     573     939        0.512     0.336     0.74 (0.4--1.368)
  BA vs. AA           HB                4     573     939        0.346     0.872     0.975 (0.715--1.329)
  BB+BA vs. AA        HB                4     573     939        0.83      0.829     0.967 (0.715--1.308)
  BB vs. BA+AA        HB                4     573     939        0.146     0.033\*   1.449 (1.031--2.036)
  B vs. A             Breast cancer     2     213     241        0.429     0.886     0.968 (0.617--1.517)
  BA vs. AA           Breast cancer     2     213     241        0.663     0.662     1.118 (0.679--1.839)
  BB+BA vs. AA        Breast cancer     2     213     241        0.533     0.867     1.042 (0.641--1.695)
  B vs. A             Gastric cancer    2     173     524        0.493     0.598     0.918 (0.669--1.261)
  BB vs. AA           Gastric cancer    2     173     524        0.259     0.168     0.481 (0.17--1.362)
  BA vs. AA           Gastric cancer    2     173     524        0.88      0.531     1.129 (0.772--1.652)
  BB+BA vs. AA        Gastric cancer    2     173     524        0.675     0.927     1.018 (0.703--1.473)
  BB vs. BA+AA        Gastric cancer    2     173     524        0.27      0.142     0.463 (0.165--1.295)
  B vs. A             Y                 6     2543    2537       0.666     0.546     1.045 (0.905--1.207)
  BB vs. AA           Y                 6     2543    2537       0.706     0.824     0.935 (0.516--1.695)
  BA vs. AA           Y                 6     2543    2537       0.683     0.436     1.065 (0.909--1.248)
  BB+BA vs. AA        Y                 6     2543    2537       0.688     0.467     1.059 (0.907--1.237)
  BB vs. BA+AA        Y                 6     2543    2537       0.693     0.771     0.916 (0.508--1.653)
  B vs. A             N                 2     299     544        0.075     0.741     1.091 (0.652--1.824)
  BB vs. AA           N                 2     299     544        0.188     0.308     0.674 (0.316--1.439)
  BA vs. AA           N                 2     299     544        0.108     0.507     0.855 (0.537--1.36)
  BB+BA vs. AA        N                 2     299     544        0.563     0.499     0.855 (0.543--1.346)
  BB vs. BA+AA        N                 2     299     544        0.073     0.789     0.716 (0.062--8.24)
  rs4696480                                                                          
  B vs. A             Overall           4     492     500        0.323     0.03\*    1.216 (1.019--1.452)
  BB vs. AA           Overall           4     492     500        0.344     0.032\*   1.463 (1.034--2.069)
  BA vs. AA           Overall           4     492     500        0.059     0.167     1.407 (0.867--2.281)
  BB+BA vs. AA        Overall           4     492     500        0.076     0.115     1.415 (0.919--2.179)
  BB vs. BA+AA        Overall           4     492     500        0.836     0.296     1.169 (0.872--1.568)
  B vs. A             Asian             2     232     230        0.628     0.772     1.039 (0.801--1.348)
  BB vs. AA           Asian             2     232     230        0.563     0.692     1.106 (0.671--1.824)
  BA vs. AA           Asian             2     232     230        0.711     0.77      0.939 (0.616--1.433)
  BB+BA vs. AA        Asian             2     232     230        0.981     0.968     0.992 (0.672--1.465)
  BB vs. BA+AA        Asian             2     232     230        0.382     0.596     1.125 (0.728--1.738)
  B vs. A             Caucasian         2     260     270        0.424     0.007\*   1.393 (1.094--1.775)
  BB vs. AA           Caucasian         2     260     270        0.406     0.009\*   1.903 (1.171--3.091)
  BA vs. AA           Caucasian         2     260     270        0.252     0.001\*   1.984 (1.307--3.012)
  BB+BA vs. AA        Caucasian         2     260     270        0.261     0.001\*   1.95 (1.317--2.887)
  BB vs. BA+AA        Caucasian         2                        0.848     0.351     1.208 (0.812--1.798)
  B vs. A             PB                3     307     319        0.21      0.176     1.167 (0.933--1.458)
  BB vs. AA           PB                3     307     319        0.217     0.152     1.369 (0.891--2.105)
  BA vs. AA           PB                3     307     319        0.044     0.421     1.322 (0.67--2.611)
  BB+BA vs. AA        PB                3     307     319        0.056     0.349     1.336 (0.729--2.449)
  BB vs. BA+AA        PB                3     307     319        0.652     0.408     1.167 (0.809--1.681)
  B vs. A             Y                 3     417     411        0.463     0.158     1.15 (0.947--1.396)
  BB vs. AA           Y                 3     417     411        0.502     0.163     1.31 (0.897--1.916)
  BA vs. AA           Y                 3     417     411        0.183     0.238     1.211 (0.881--1.665)
  BB+BA vs. AA        Y                 3     417     411        0.227     0.158     1.239 (0.921--1.666)
  BB vs. BA+AA        Y                 3     427     411        0.677     0.412     1.146 (0.827--1.588)
  rs5743708                                                                          
  B vs. A             Overall           2     309     572        \<0.001   0.321     4.076 (0.255--65.24)
  BA vs. AA           Overall           2     309     572        0.022     0.338     1.697 (0.575--5.011)
  BB+BA vs. AA        Overall           4     2618    3487       \<0.001   0.312     1.651 (1.348--2.022)
  rs1898830                                                                          
  B vs. A             Overall           3     2520    3146       0.391     0.939     1.003 (0.928--1.085)
  BB vs. AA           Overall           3     2520    3146       0.323     0.646     0.961 (0.809--1.14)
  BA vs. AA           Overall           3     2520    3146       0.056     0.806     0.971 (0.768--1.227)
  BB+BA vs. AA        Overall           3     2520    3146       0.075     0.813     0.975 (0.791--1.202)
  BB vs. BA+AA        Overall           3     2520    3146       0.998     0.77      0.977 (0.835--1.143)
  B vs. A             Caucasian         2     2309    2914       0.623     0.655     1.019 (0.939--1.106)
  BB vs. AA           Caucasian         2     2309    2914       0.779     0.972     1.003 (0.837--1.202)
  BA vs. AA           Caucasian         2     2309    2914       0.515     0.355     1.056 (0.941--1.187)
  BB+BA vs. AA        Caucasian         2     2309    2914       0.518     0.433     1.045 (0.936--1.167)
  BB vs. BA+AA        Caucasian         2     2309    2914       0.955     0.777     0.975 (0.822--1.158)
  B vs. A             PB                2     2309    2914       0.623     0.655     1.019 (0.939--1.106)
  BB vs. AA           PB                2     2309    2914       0.779     0.972     1.003 (0.837--1.202)
  BA vs. AA           PB                2     2309    2914       0.515     0.355     1.056 (0.941--1.187)
  BB+BA vs. AA        PB                2     2309    2914       0.518     0.433     1.045 (0.936--1.167)
  BB vs. BA+AA        PB                2     2309    2914       0.955     0.777     0.975 (0.822--1.158)

Abbreviations: *n*, polymorphisms did not conform to HWE in the control group; P-B, population based; *P~H~*, *P*-value of Q test for heterogeneity test; *P*~Z~, means statistically significant (*P*\<0.05); Y, polymorphisms conformed to HWE in the control group.

\* *P*-value less than 0.05 was considered as statistically significant.

There are nine studies on rs3804099 polymorphism including a total of 3456 cases and 4574 controls \[[@B13],[@B18],[@B37]\]. According to overall analysis, rs3804099 significantly decreased cancer risk \[BA vs. AA (OR = 0.827, 95% Cl = 0.717--0.952, *P*=0.008), BB+BA vs. AA (OR = 0.85, 95% Cl = 0.744--0.97, *P*=0.016)\] ([Figure 3](#F3){ref-type="fig"}). About Asians, rs3804099 polymorphism reduced the risk of cancer in the model of BA vs. AA (OR = 0.69, 95% Cl = 0.55--0.867, *P*=0.001) and BB vs. AA (OR = 0.65, 95% Cl = 0.482--0.877, *P*=0.005). In the subgroup of gastric cancer patients, we found that rs3804099 polymorphism reduced the risk of cancer \[B vs. A (OR = 0.728, 95% Cl = 0.594--0.893, *P*=0.002), BB vs. AA (OR = 0.605, 95% Cl = 0.389--0.942, *P*=0.026), BA vs. AA (OR = 0.706, 95% Cl = 0.529--0.942, *P*=0.018), BB+BA vs. AA (OR = 0.681, 95% Cl = 0.524--0.886, *P*=0.004)\] and the model of BB vs. BA+AA is not associated with reduced risk of gastric cancer. Part of the model in the hospital-based analysis was associated with reduced cancer risk \[BA vs. AA (OR = 0.713, 95% Cl = 0.564--0.902, *P*=0.005), BB+BA vs. AA (OR = 0.734, 95% Cl = 0.591--0.912, *P*=0.005)\].

![Meta-analysis of the association between *TLR2* rs3804009 del polymorphism and cancer risk](bsr-39-bsr20191698-g3){#F3}

There are four studies on rs4696480 polymorphism including a total of 492 cases and 500 controls \[[@B14],[@B17],[@B18],[@B38]\]. In some models of the overall analysis, rs4696480 significantly increased cancer risk \[B vs. A (OR = 1.216, 95% Cl = 1.019--1.452, *P*=0.03); BB vs. AA (OR = 1.463, 95% Cl = 1.034--2.069, *P*=0.032)\]. It is worth mentioning that rs4696480 makes Caucasians more susceptible to cancer \[B vs. A (OR = 1.393, 95% Cl = 1.094--1.775, *P*=0.007), BB vs. AA (OR = 1.903, 95% Cl = 1.171--3.091, *P*=0.009), BA vs. AA (OR = 1.984, 95% Cl = 1.307--3.012, *P*=0.001), BB+BA vs. AA (OR = 1.95, 95% Cl = 1.317--2.887, *P*=0.001)\]. Thus, we can conclude that a subgroup analysis by ethnicity suggests that rs4696480 is related to cancer risk in Caucasians, but not in other ethnic groups ([Table 2](#T2){ref-type="table"} and Supplementary Figure S1).

For rs3804100 polymorphism, we collected eight publications which contained 2842 cases and 3081 controls \[[@B1],[@B13],[@B18],[@B38],[@B41]\]. But only in hospital-based analysis we found the model of BB vs. BA+AA (OR = 1.449, 95% Cl = 1.031--2.036, *P*=0.033) added to the risk of cancer. None of the other models showed any association between rs3804100 and cancer risk, either in the analysis of overall group or in other subgroups ([Table 2](#T2){ref-type="table"} and Supplementary Figure S2).

As for rs5743708 \[[@B6],[@B37],[@B42]\] and rs1898830 \[[@B16],[@B37]\], they were found to have no significant correlation with cancer, either in overall analysis or in other subgroup analysis ([Table 2](#T2){ref-type="table"} and Supplementary Figures S3 and S4).

Sensitivity analysis and publication bias {#sec3-3}
-----------------------------------------

By the way, we removed individual study one by one when conducted the sensitivity analysis. We did not observe any significant changes in the OR and corresponding 95% CI values, so the stability of our results was confirmed. All the details of sensitivity analysis are shown in the Supplementary Table S2 and Figure S5.

We used the Begg's test to evaluate publication bias for selected literature. These funnel plots in [Figure 4](#F4){ref-type="fig"} showed the relationship between the cancer risk and the *TLR2* polymorphism in this meta-analysis. Among the various polymorphic sites, the funnel plots were symmetrically distributed. This showed that there was no publication bias. The Egger's test further analyzed the publication bias, and showed that no significant evidence of publication bias was observed in our study (*P*=0.937 for SNP rs4696480; *P*=0.291 for - 196 to - 174del polymorphism; *P*=0.991 for SNP rs3804099) (Supplementary Table S3).

![Begg's funnel plot for *TLR2* polymorphisms and overall cancer publication bias (B vs. A)\
For Begg's funnel plot, the x-axis is log (OR), and the y-axis is natural logarithm of OR. The horizontal line in the figure represents the overall estimated log (OR). The two diagonal lines indicate the pseudo 95% confidence limits of the effect estimate.](bsr-39-bsr20191698-g4){#F4}

Results of FPRP and TSA {#sec4}
=======================

The FPRP values for positive findings at different prior probability levels are shown in [Table 3](#T3){ref-type="table"}. For -196 to -174del variant, almost all the statistical power high than 0.2, for the FPRP values, under the prior probability of 0.25, the FPRP values for each group is less than 0.2, except the five genetic models about Caucasian subgroup. Which means that the results on Caucasian subgroup are not stable, more studies are needed to illustrate the results. For the other positive results on rs3804099, rs3804100 and rs4696480, almost all the statistical power was higher than 0.5, and under the prior probability of 0.25, the FPRP values for each group is less than 0.2, which means that the results are reliable. The results of TSA are shown in [Figure 5](#F6){ref-type="fig"}, we analyzed the required sample size of each polymorphism. The required sample size of -196 to -174del variant is approximately 39020, although the sample size in the current study did not meet the required number, we observed that the cumulative z-curve crossed the trial sequential monitoring boundary and the traditional significant boundary (Z = 1.96, α = 0.05), which means that our conclusions were robust with the sufficient evidence. For rs3804100 (required sample size: 9162) and rs4696480 (required sample size: 1984), we observed that the cumulative z-curve crossed the trial sequential monitoring boundary and the traditional significant boundary, and meet the required number. The TSA result about rs1898830 showed that the mutant allele performed the similar impact on cancer risk compare with the wild allele, no more samples are needed to confirm the result ([Figure 5](#F5){ref-type="fig"}). However, The TSA results of rs3804099 and rs5743708 indicated that more objects are need to drag out the robust conclusion (Supplementary Figure S6).

![TSA for *TLR2* polymorphism under the allele contrast model (B vs. A)](bsr-39-bsr20191698-g5){#F5}

###### FPRP values for associations between the risk of cancer and the frequency of genotypes

  Comparison              Subgroup         *n*   P~Z~      OR (95% CI)             Statistical power                                 
  ----------------------- ---------------- ----- --------- ----------------------- ------------------- ---------- ---------- ------- -------
  **(-196 to -174del)**                                                                                                              
  B vs. A                 Overall          18    0.005\*   1.468 (1.129--1.91)     0.564               0.022^†^   0.064^†^   0.427   0.883
  BB vs. AA               Overall          18    0.005\*   1.716 (1.178--2.5)      0.237               0.054^†^   0.146^†^   0.652   0.950
  BA vs. AA               Overall          18    0.008\*   1.408 (1.092--1.816)    0.683               0.035^†^   0.099^†^   0.547   0.924
  BB+BA vs. AA            Overall          18    0.007\*   1.449 (1.107--1.897)    0.597               0.034^†^   0.096^†^   0.539   0.922
  BB vs. BA+ AA           Overall          18    0.013\*   1.517 (1.092--2.107)    0.468               0.073^†^   0.192^†^   0.723   0.963
  B vs. A                 Asian            11    0.043\*   1.169 (1.005--1.361)    0.999               0.117^†^   0.285      0.814   0.978
  BB+BA vs. AA            Asian            11    0.033\*   1.203 (1.015--1.427)    0.994               0.106^†^   0.262      0.796   0.975
  B vs. A                 Caucasian        3     0.028\*   3.291 (1.139--9.51)     0.073               0.532      0.773      0.974   0.997
  BB vs. AA               Caucasian        3     0.008\*   9.878 (1.83--53.322)    0.014               0.621      0.831      0.982   0.998
  BA vs. AA               Caucasian        3     0.044\*   3.156 (1.034--9.634)    0.096               0.577      0.804      0.978   0.998
  BB+BA vs. AA            Caucasian        3     0.034\*   3.555 (1.098--11.51)    0.075               0.579      0.805      0.978   0.998
  BB vs. BA+ AA           Caucasian        3     0.006\*   7.294 (1.752--30.369)   0.015               0.561      0.793      0.977   0.998
  B vs. A                 PB               14    0.001\*   1.576 (1.193--2.08)     0.364               0.011^†^   0.031^†^   0.263   0.783
  BB vs. AA               PB               14    0.001\*   2.274 (1.43--3.616)     0.040               0.039^†^   0.108^†^   0.571   0.931
  BA vs. AA               PB               14    0.005\*   1.543 (1.143--2.081)    0.427               0.031^†^   0.086^†^   0.510   0.913
  BB+BA vs. AA            PB               14    0.002\*   1.624 (1.186--2.223)    0.310               0.023^†^   0.067^†^   0.441   0.888
  BB vs. BA+ AA           PB               14    0.001\*   2.011 (1.317--3.07)     0.087               0.040^†^   0.111^†^   0.578   0.933
  B vs. A                 Y                15    0.008\*   1.447 (1.103--1.897)    0.603               0.036^†^   0.101^†^   0.551   0.925
  BB vs. AA               Y                15    0.004\*   1.915 (1.227--2.991)    0.141               0.083^†^   0.214      0.750   0.968
  BA vs. AA               Y                15    0.02\*    1.422 (1.057--1.915)    0.637               0.088^†^   0.224      0.760   0.970
  BB+BA vs. AA            Y                15    0.013\*   1.494 (1.088--2.052)    0.510               0.072^†^   0.189      0.719   0.963
  BB vs. BA+ AA           Y                15    0.009\*   1.673 (1.137--2.461)    0.290               0.085^†^   0.218      0.754   0.969
  BA vs. AA               N                3     0.039\*   1.335 (1.015--1.757)    0.797               0.129^†^   0.307      0.830   0.980
  **rs3804099**                                                                                                                      
  BA vs. AA               Overall          9     0.008\*   0.827 (0.717--0.952)    0.999               0.024^†^   0.069^†^   0.448   0.891
  BB+BA vs. AA            Overall          9     0.016\*   0.85 (0.744--0.97)      1.000               0.045^†^   0.125^†^   0.611   0.941
  BB vs. AA               Asian            5     0.005\*   0.65 (0.482--0.877)     0.434               0.032^†^   0.091^†^   0.524   0.917
  BA vs. AA               Asian            5     0.001\*   0.69 (0.55--0.867)      0.287               0.064^†^   0.170^†^   0.692   0.958
  B vs. A                 Gastric cancer   2     0.002\*   0.728 (0.594--0.893)    0.801               0.009^†^   0.025^†^   0.223   0.743
  BB vs. AA               Gastric cancer   2     0.026\*   0.605 (0.389--0.942)    0.334               0.190^†^   0.413      0.886   0.987
  BA vs. AA               Gastric cancer   2     0.018\*   0.706 (0.529--0.942)    0.652               0.076^†^   0.199^†^   0.732   0.965
  BB+BA vs. AA            Gastric cancer   2     0.004\*   0.681 (0.524--0.886)    0.563               0.022^†^   0.063^†^   0.426   0.882
  BB vs. BA+ AA           Colon cancer     2     0.034\*   0.841 (0.716-0.987)     0.998               0.093^†^   0.235      0.771   0.971
  BA vs. AA               HB               4     0.005\*   0.713 (0.564--0.902)    0.712               0.020^†^   0.057^†^   0.400   0.871
  BB+BA vs. AA            HB               4     0.005\*   0.734 (0.591--0.912)    0.807               0.019^†^   0.055^†^   0.391   0.867
  B vs. A                 Y                5     0.036\*   0.895 (0.807--0.993)    1.000               0.098^†^   0.247      0.783   0.973
  BB+BA vs. AA            Y                5     0.028\*   0.844 (0.725--0.982)    0.999               0.078^†^   0.202      0.736   0.966
  BA vs. AA               N                4     0.042\*   0.73 (0.54--0.988)      0.722               0.147^†^   0.341      0.851   0.983
  **rs3804100**                                                                                                                      
  BB vs. BA+ AA           HB               4     0.033\*   1.449 (1.031--2.036)    0.579               0.144^†^   0.336      0.848   0.983
  **rs4696480**                                                                                                                      
  B vs. A                 Overall          4     0.03\*    1.216 (1.019--1.452)    0.990               0.085^†^   0.218      0.754   0.969
  BB vs. AA               Overall          4     0.032\*   1.463 (1.034--2.069)    0.556               0.145^†^   0.337      0.848   0.983
  B vs. A                 Caucasian        2     0.007\*   1.393 (1.094--1.775)    0.725               0.029^†^   0.084^†^   0.501   0.910
  BB vs. AA               Caucasian        2     0.009\*   1.903 (1.171--3.091)    0.168               0.143^†^   0.333      0.846   0.982
  BA vs. AA               Caucasian        2     0.001\*   1.984 (1.307--3.012)    0.095               0.040^†^   0.110^†^   0.576   0.932
  BB+BA vs. AA            Caucasian        2     0.001\*   1.95 (1.317--2.887)     0.095               0.026^†^   0.075^†^   0.470   0.899

Statistical power was calculated using the number of observations in the subgroup and the OR and *P* values in this table. Abbreviations: CI, confidence interval; H-B, hospital based; HWE (Y), polymorphisms conformed to HWE in the control group.

\**P*-value less than 0.05 was considered as statistically significant.

^†^The significant result with the FPRP values less than 0.2 was considered a worthy finding.

LD analyses and *in-silico* analysis of *TLR2* expression {#sec4-1}
---------------------------------------------------------

LD analysis was conducted to evaluate the presence of bins in different *TLR2* polymorphisms, aiming to understand the internal linkages, the results of which are shown in [Figure 6](#F6){ref-type="fig"}. Highlighted, there is significant LD between rs4696480 and rs1898830 in CEU, CHB and CHS, and JPT populations (CEU: r^2^ = 0.52; CHB and CHS: r^2^ = 0.90; JPT: r^2^ = 1.0). The LD between rs3804099 and rs3804100 is also remarkable in CHB and CHS and JPT populations (CHB and CHS: r^2^ = 0.85; JPT: r^2^ = 0.86) (Supplementary Table S4). According to the result on GTEx portal data, we found that the mutant allele leads to an increase expression of TLR2 mRNA in rs1898830 (*P*=3.5\*10^−17^), while the mutant allele of rs3804099 (*P*=2.5\*10^−14^), rs3804100 (*P*=9.7\*10^−5^) and rs4696480 (*P*=1.2\*10^−5^) lead to a decreased expression of TLR2 ([Figure 7](#F7){ref-type="fig"}).

![LD analyses for TLR2 polymorphisms in populations from 1000 genomes Phase 3\
The number of each cell represents r^2^ and white color cells show no LD between polymorphisms.](bsr-39-bsr20191698-g6){#F6}

![*In-silico* analysis of TLR2 expression concerned to its polymorphisms](bsr-39-bsr20191698-g7){#F7}

Discussion {#sec5}
==========

TLRs are expressed in mast cells and several other cell types, which could recognize microbial components and trigger inflammatory response. *TLR2* is type I transmembrane transporter which plays an important role in immune inflammatory response \[[@B43]\], and have been shown to influence host defense and disease progression \[[@B44]\]. There have been four previous meta-analyses on *TLR2*. But two of the studies were limited to gastric cancer \[[@B45],[@B46]\]. One of these articles suggested that - 196 to - 174del was associated with the rise of cancer risk and the rs3804099 can decrease cancer risk \[[@B47]\]. Another article suggested that -196 to -174del had no relationship with cervical cancer \[[@B48]\]. For assessing the real influence of *TLR2* on cancer risk, we collected more samples than before. And our meta-analysis combines many types of cancers to study the relationship between *TLR2* polymorphism and cancer risk as comprehensively as possible.

For -196 to -174del, it is a 22-bp deletion at the promoter region of *TLR2* gene. Transcriptional reduction in the *TLR2* gene due to this substitution may significantly alter the function of the promoter \[[@B49]\]. Chen et al.'s meta-analysis \[[@B45]\] thought that this polymorphism is not associated with gastric cancer. Yang et al. \[[@B48]\] published a meta-analysis in 2018 suggesting that -196 to -174del had nothing to do with cervical cancer. And in our calculations, we revealed that the deletion of these 22 genes does increase the risk of cancer, especially among Caucasians. However, the subgroup calculations of gastric, breast and cervical cancers had no obvious significance.

Synonymous mutations are associated with disease, such as rs3804099 and rs3804100 of *TLR2* \[[@B16]\]. We found that rs3804099 is protective against gastric cancer which is consistent with Wang et al. \[[@B47]\]. As for rs3804100, unfortunately, we only came to the conclusions related to cancer in the subgroup of hospital-based. This conclusion is extremely contingent because of the small number of samples and the limitations of the source of the sample. Taking into account the vast majority of calculations and references, we reserve the conclusion that rs3804100 is not related to cancer. And we are the first meta-analysis involving rs4696480. The overall analysis of B vs. A and BB vs. AA shown that rs4696480 has increased the risk of cancer. At the same time, the calculation results also show that its influence on cancer is particularly obvious among the Caucasian population.

Although our conclusions about -196 to -174del, rs3804099 and rs3804100 are consistent with the previous two meta-analyses, we included more case--control studies, so our meta-analysis is more convincing. And we also clearly observe that 'ethnic' factors are critical in assessing the role of *TLR2* in cancer risk. The calculation of -196 to -174del and rs4696480 both found that Caucasians make a significant increase in the cancer risk. And in the model of BB vs. AA and BA vs. AA, rs3804099 deduce the cancer risk in Asians. Furthermore, as the results showing -196 to -174del and rs4696480 are associated with the tumorigenesis, so that these polymorphisms could be a potential biomarker to remind people with the polymorphism pay more attention to the occurrence of cancer, and solve the problem as soon as possible. In the current study, we also evaluated the LD between different polymorphisms of TLR2, we found that there are significantly LD among rs4696480 and rs1898830, rs3804099 and rs3804100. Based on the results, it could guide the researchers to put these polymorphisms together when assess their effect on cancer risks or other bioscience mechanisms. At the same time, we should also be aware of some of the limitations of our article. First of all, based on the results of TSA, we found that the sample size of -196 to -174 del, rs3804100 and rs4696480 is enough to generate the reliable conclusion in the current study, however, larger number of patients are needed to confirm the effect of rs3804099, rs1898830 and rs5743708 to cancer risks. Second, we lack in-depth studies of the effects of environment, lifestyle, bacterial infections and other factors of cancer risk.

Conclusion {#sec6}
==========

Our meta-analysis suggested that -196 to -174del increased the risk of cancer; rs4696480 increases the risk of cancer in Caucasians; rs3804099 reduced the risk of cancer, especially gastric cancer. While there is no direct evidence showing that rs5743708,3804100 and rs1898830 are related to cancer.
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CEU

:   Utah residents with Northern and Western European ancestry from the CEPH collection

CHB

:   Han Chinese in Beijing, China

CHS

:   Southern Han Chinese, China

FPRP

:   false-positive report probability

HWE

:   Hardy--Weinberg equilibrium

JPT

:   Japanese in Tokyo, Japan

LD

:   linkage disequilibrium

NOS

:   Newcastle--Ottawa Scale

OR

:   odds ratio

*TLR2*

:   Toll-like receptor-2

TSA

:   trial sequential analysis

95% CI

:   95% confidence interval
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